Evidence map›Paper›PMID 42920190›Full record

ArticleJournal of translational medicine2026

SPP1⁺ macrophage-derived WNT5A contributes to MMP11⁺ myCAF-mediated matrix remodeling and immunotherapy resistance in lung adenocarcinoma.

Menglei Wang, Pengcheng Zhang, Xuefeng Li, Lan Shao, Shijie Dai, Zhuo Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Menglei Wang *Zhejiang Cancer Hospital, Hangzhou, China.
Pengcheng Zhang *Zhejiang Chinese Medical University, Hangzhou, China.
Xuefeng Li *Department of Orthopedics, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Lan ShaoZhejiang Cancer Hospital, Hangzhou, China.
Shijie DaiZhejiang Chinese Medical University, Hangzhou, China. dsj2513140@163.com.
Zhuo ChenZhejiang Cancer Hospital, Hangzhou, China. chenzhuo@zjcc.org.cn.

Funding

National Natural Science Foundation of China 82505233Traditional Chinese Medicine Scientific Research Foundation of Zhejiang Province 2026ZL0017
6 · The paper itself

Abstract

backgroundLung adenocarcinoma (LUAD) is the leading subtype of non-small cell lung cancer. However, the stromal-immune circuits that coordinate matrix remodeling and immunotherapy resistance in LUAD remain incompletely understood. This study aimed to characterize the stromal-immune interactions associated with LUAD progression and poor response to PD-1 blockade.

methodsBulk transcriptomic datasets, single-cell RNA sequencing, and spatial transcriptomic data were integrated with clinical immunotherapy cohorts. Weighted gene co‑expression network analysis, survival meta‑analysis, and tissue enrichment scoring identified high‑risk cell subpopulations. Cell‑cell communication, virtual gene knockout, and spatial deconvolution were used to predict ligand‑receptor interactions and colocalization. Multiplex immunohistochemistry of clinical specimens validated spatial relationships. In vitro, MMP11-overexpressing cancer-associated fibroblasts (CAFs) and SPP1-overexpressing macrophages (Macs) were generated, and a macrophage-CAF co‑culture system was constructed. Migration, contractility, extracellular matrix deposition, and YAP/INHBA pathway activation was measured. In vivo, a murine tumor model was established and evaluated using in vivo imaging, flow cytometry, atomic force microscopy assay, HE, masson staining, and multiplexed IHC staining.

resultsMMP11⁺ myofibroblastic CAF (MMP11⁺ myCAF) was identified as a high-risk CAF subset enriched in primary tumor and metastatic lesions, characterized by elevated expression of matrix-remodeling and contractile genes, including MMP11, ACTA2, and TAGLN. Increased abundance of MMP11⁺ myCAF was associated with advanced tumor stage, metastasis, poor overall survival, and reduced benefit from immune checkpoint blockade (ICB). Spatial transcriptomic deconvolution and multiplex immunohistochemistry revealed that MMP11⁺ myCAFs spatially co-localized with SPP1⁺ Mac, a pro-tumor myeloid population enriched in malignant and metastatic LUAD tissues. Ligand-receptor and downstream target analyses identified WNT5A as a key macrophage-derived mediator linking SPP1⁺ Mac to MMP11⁺ myCAF activation. Mechanistically, SPP1⁺ Mac exhibited activation of NFKB2/RELB-associated transcriptional programs, and SPP1 overexpression increased Nfkb2, Relb, and WNT5A protein levels in macrophages. WNT5A stimulation promoted YAP/INHBA-associated signaling in CAFs, enhancing CAF migration, contractility and extracellular matrix deposition. In animal models, activation of WNT5A signaling impaired the therapeutic efficacy of PD-1 blockade, reduced intratumoral CD8⁺ T-cell infiltration, and increased MMP11⁺ CAF-associated collagen deposition and tissue stiffness.

conclusionsSPP1⁺ Mac-derived WNT5A may contribute to MMP11⁺ myCAF-mediated matrix remodeling and immunotherapy resistance in LUAD, highlighting a potential therapeutic strategy to overcome ICB resistance.

Indexed as

Adenocarcinoma of LungDrug Resistance, NeoplasmExtracellular MatrixImmunotherapyLung NeoplasmsMacrophagesMatrix Metalloproteinase 11Wnt-5a ProteinAnimalsCancer-Associated FibroblastsCell Line, TumorFemaleGene Expression Regulation, NeoplasticHumansMiceMatrix Metalloproteinase 11Wnt-5a ProteinCancer-associated fibroblastImmunotherapyLung adenocarcinomaMatrix remodelingTumor-associated macrophage

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.